PBYI - Puma Biotechnology Inc logo

PBYI

Puma Biotechnology Inc

Rev โ€”top 1%10Y
Hold

Puma Biotechnology develops and commercializes cancer treatments, including NERLYNX for early-stage and advanced HER2-positive breast cancer. It also works on alisertib for various cancer types, using specialty pharmacy networks for distribution.

โš•๏ธ Healthcare NASDAQ Listed 2012 $ USD
$1,000 invested 10 years ago โ†’$183today

Score Overview

1 Year
Score
Net Growth-14.12%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth1.26%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score6.4
Net Growth191.73%
Net Trend80%
Net Income Consistencyโ€”
Rev Growth-8.66%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Scoreโ€”
Net Growth109.68%
Net Trend80%
Net Income Consistency
Rev Growthโ€”
Rev Trend60%
Revenue Consistency
All Time
Scoreโ€”
Net Growth135.96%
Net Trend64%
Net Income Consistency
Rev Growthโ€”
Rev Trend43%
Revenue Consistency

See the full market ranking โ†’

Puma Biotechnology Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 225M to $ 228M and net income went from -$ 59M to $ 31M. Revenue increased in 2 of those 5 years; net income in 4.

Puma Biotechnology Inc currently holds a 5-year HDB Score of 6.4 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 8.90โ€”
1 Year2025-08-12
$ 4.8782.75%
5 Years2021-08-12
$ 7.2822.25%
10 Years2016-08-12
$ 48.63-81.70%
All Time2012-04-24
$ 14.00-36.43%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 231M$ 26M$ 93M
2025$ 228M$ 31M$ 97M
2024$ 230M$ 30M$ 100M
2023$ 235M$ 21M$ 95M
2022$ 228M$ 2K$ 81M
2021$ 253M-$ 29M$ 82M
2020$ 225M-$ 59M$ 93M
2019$ 272M-$ 75M$ 111M
2018$ 251M-$ 113M$ 108M
2017$ 27M-$ 292M$ 81M
2016$ 0.00-$ 276M$ 194M
2015$ 0.00-$ 239M$ 31M
2014$ 0.00-$ 142M$ 38M
2013$ 0.00-$ 54M$ 83M
IPO2012$ 0.00-$ 74M$ 137M

Explore beyond PBYI

You're looking at Puma Biotechnology Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies